New drug combo shows promise in shrinking tumors before breast cancer surgery
NCT ID NCT04126525
Summary
This study tested whether adding a drug called pyrotinib to standard chemotherapy and trastuzumab before surgery could better shrink tumors in women with HER2-positive breast cancer. The treatment was given to 53 women with early-stage disease to see if it could eliminate all cancer cells before their surgery. Researchers measured how many patients achieved complete tumor disappearance and monitored side effects of the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Renji Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.